PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
加利福尼亞州聖何塞，2024 年 4 月 2 日（GLOBE NEWSWIRE）— PROCEPT 生物機器人 公司 （“公司”）（納斯達克股票代碼：PRCT）是一家專注於通過開發泌尿外科變革性解決方案來促進患者護理的手術機器人公司。該公司今天宣佈，將在2024年5月1日星期三收盤後公佈2024年第一季度的財務業績。公司管理層將從美國東部時間上午 8:00 開始舉行相應的電話會議。
Investors interested in listening to the conference call may do so by following one of the below links:
有興趣收聽電話會議的投資者可以通過以下鏈接之一收聽電話會議：
- Webcast link for interested listeners:
- 感興趣的聽衆的網絡直播鏈接：
- Dial-in registration for sell-side research analysts:
Live audio of the webcast will be available on the "Investors" section of the Company's website at: https://ir.procept-biorobotics.com.
網絡直播的直播音頻將在公司網站的 “投資者” 部分提供，網址爲： https://ir.procept-biorobotics.com。
An archived recording will be available on the "Investors" section of the Company's website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.
存檔錄音將在公司網站的 “投資者” 欄目中公佈，網址爲： https://ir.procept-biorobotics.com。每個網絡直播將在活動結束後的至少 90 天內可供重播。
The Company also announced today that members of management will present at the upcoming Bank of America 2024 Health Care Conference in Las Vegas. Management is scheduled to present on Wednesday, May 15 at 9:20 a.m. Pacific Time. A live webcast of the event, as well as an archived recording, will be available on the "Investors" section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
該公司今天還宣佈，管理層成員將出席即將在拉斯維加斯舉行的美國銀行2024年醫療保健會議。管理層定於太平洋時間5月15日星期三上午9點20分發表演講。該活動的網絡直播以及存檔錄音將在公司網站的 “投資者” 欄目上提供，網址爲： https://ir.procept-biorobotics.com。網絡直播將在活動結束後至少 90 天內存檔並可供重播。
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
關於 PROCEPT BioRobotics 公司
PROCEPT BioRobotics是一家手術機器人公司，致力於通過開發泌尿科變革性解決方案來促進患者護理。PROCEPT BioRobotics開發、製造和銷售AquaBeam機器人系統，這是一種先進的圖像引導手術機器人系統，用於微創泌尿外科手術，最初的重點是治療良性前列腺增生（BPH）。良性前列腺增生是最常見的前列腺疾病，在美國影響約4000萬男性。PROCEPT BioRobotics 設計的水消融療法旨在爲因良性前列腺增生引起的下尿路症狀或 LUTS 的男性提供有效、安全和持久的療效，這些症狀與前列腺大小和形狀或外科醫生的經驗無關。該公司已經開發了大量且不斷增長的臨床證據，其中包括九項臨床研究和150多份經過同行評審的出版物，這些證據支持了Aquablation療法的益處和臨床優勢。
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@PROCEPT-BioRobotics.com
投資者聯繫人：
Matt Bacso
投資者關係和業務運營副總裁
m.bacso@PROCEPT-BioRobotics.com
譯文內容由第三人軟體翻譯。